Search

Your search keyword '"Conyers, Rachel"' showing total 235 results
Start Over Author "Conyers, Rachel"
235 results on '"Conyers, Rachel"'

3. Protocol for a prospective feasibility study investigating phenoconversion of CYP3A4, CYP2C19 and CYP2D6 genotype in paeidiatric, adolescent and young adult patients with an acute diagnosis of Hodgkin or Non Hodgkin Lymphoma (PEGASUS)

Author

Conyers, Rachel, primary, Stenta, Tayla, additional, Felmingham, Ben, additional, Somogyi, Andrew, additional, Kirkpatrick, Carl, additional, Halman, Andreas, additional, Moore, Claire, additional, Khatri, Dhrita, additional, Williams, Elizabeth, additional, Dyas, Roxanne, additional, Elliott, David A., additional, Gwee, Amanda, additional, and Alexander, Marliese, additional

Published
2024
Full Text
View/download PDF

4. Cardio-Oncology Recommendations for Pediatric Oncology Patients: An Australian and New Zealand Delphi Consensus

Author

Toro, Claudia, Felmingham, Ben, Jessop, Sophie, Celermajer, David S., Kotecha, Rishi S., Govender, Dinisha, Terese Hanna, Diane Marie, O'Connor, Matthew, Manudhane, Rebecca, Ayer, Julian, O'Sullivan, John, Sullivan, Michael, Costello, Ben, La Gerche, André, Walwyn, Thomas, Horvath, Lisa, Mateos, Marion K., Fulbright, Joy, Jadhav, Mangesh, Cheung, Michael, Eisenstat, David, Elliott, David A., and Conyers, Rachel

Published
2022
Full Text
View/download PDF

5. Prospective longitudinal evaluation of treatment-related toxicity and health-related quality of life during the first year of treatment for pediatric acute lymphoblastic leukemia

Author

Schilstra, Clarissa E., McCleary, Karen, Fardell, Joanna E., Donoghoe, Mark W., McCormack, Emma, Kotecha, Rishi S., Lourenco, Richard De Abreu, Ramachandran, Shanti, Cockcroft, Ruelleyn, Conyers, Rachel, Cross, Siobhan, Dalla-Pozza, Luciano, Downie, Peter, Revesz, Tamas, Osborn, Michael, Alvaro, Frank, Wakefield, Claire E., Marshall, Glenn M., Mateos, Marion K., and Trahair, Toby N.

Published
2022
Full Text
View/download PDF

6. ANZTCT practice statement: sinusoidal obstruction syndrome/veno‐occlusive disease diagnosis and management.

Author

Fleming, Shaun, Scott, Ashleigh P., Coutsouvelis, John, Fraser, Chris, Bajel, Ashish, Nelson, Adam, Conyers, Rachel, McEwan, Ashley, Yeung, David, Campion, Victoria, Teague, Lochie, McGuire, Matthew, Morris, Edward, Gabriel, Melissa, Wayte, Rebecca, Douglas, Genevieve, Chien, Nicole, and Hamad, Nada

Subjects
LUNG disease diagnosis, LUNG disease prevention, THERAPEUTIC use of monoclonal antibodies, MEDICAL protocols, HEMATOPOIETIC stem cell transplantation, BLOOD, DISEASE management, PEDIATRICS, LUNG diseases, HEPATIC veno-occlusive disease, BONE marrow transplantation
Abstract

Sinusoidal obstruction syndrome/veno‐occlusive disease (SOS/VOD) is a life‐threatening complication which can develop after haemopoietic stem cell transplantation (HSCT) and some antibody–drug conjugates. Several SOS/VOD diagnostic and management guidelines exist, with the most recent and refined being the European Society for Blood and Marrow Transplantation adult and paediatric guidelines. Timely diagnosis and effective management (including the availability of therapeutic options) significantly contribute to improved patient outcomes. In Australia and New Zealand, there is variability in clinical practice and access to SOS/VOD therapies. This review aims to summarise the current evidence for SOS/VOD diagnosis, prevention and treatment and to provide recommendations for SOS/VOD in the context of contemporary Australasian HSCT clinical practice. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. Benchmarking pharmacogenomics genotyping tools: Performance analysis on short‐read sequencing samples and depth‐dependent evaluation.

Author

Halman, Andreas, Lunke, Sebastian, Sadedin, Simon, Moore, Claire, and Conyers, Rachel

Subjects
WHOLE genome sequencing, CYTOCHROME P-450 CYP2D6, GENOMES, GENETICS, ALLELES
Abstract

Pharmacogenomics (PGx) investigates the influence of genetics on drug responses, enabling tailored treatments for personalized healthcare. This study assessed the accuracy of genotyping six genes using whole genome sequencing with four different computational tools and various sequencing depths. The effects of using different reference genomes (GRCh38 and GRCh37) and sequence aligners (BWA‐MEM and Bowtie2) were also explored. The results showed generally minor variations in tool performance across most genes; however, more notable discrepancies were observed in the analysis of the complex CYP2D6 gene. Cyrius, a CYP2D6‐specific tool, demonstrated the most robust performance, achieving the highest concordance rates for CYP2D6 in all instances, comparable to the consensus approach in most cases. There were rather small differences between the samples with 20× coverage depth and those with higher depth, but the decreased performance was more evident at lower depths, particularly at 5×. Additionally, variations in CYP2D6 results were observed when samples were aligned to different reference genomes using the same method, or to the same genome using different aligners, which led to reporting incorrect rare star alleles in several cases. These findings inform the selection of optimal PGx tools and methodologies as well as suggest that employing a consensus approach with two or more tools might be preferable for certain genes and tool combinations, especially at lower sequencing depths, to ensure accurate results. Additionally, we show how the upstream alignment can affect the performance of tools, an important factor to take into account. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia

Author

Attarbaschi, Andishe, Adams, Madeline R, Andres-Jensen, Liv, Bardi, Edit, Barzilai-Birenboim, Shlomit, Baust, Katja, Bhojwani, Deepa, Boesten, Tineke, Calaminus, Gabriele, Conyers, Rachel, Darlington, Anne-Sophie, de Ville, Maëlle, Escherich, Gabriele, Hagleitner, Melanie, Halsey, Christina, Harila-Saari, Arja, Hou, Jen-Yin, Huang, Ting-Huan, Hudson, Melissa, Jeha, Sima, Jenney, Meriel, Kato, Motohiro, Krawczuk-Rybak, Maryna, Kremer, Leontine, Lautem, Melchior, Liu, Hse-Che, Lopez Lopez, Elixabet, Mateos, Marion, Mlynarski, Wojciech, Möricke, Anja, Muszynska-Roslan, Katarzyna, Niinimaki, Riitta, Pieters, Rob, Piette, Caroline, Raetz, Elizabeth, Ronceray, Leila, Schmiegelow, Kjeld, Toro, Claudia, Trahair, Toby, Valsecchi, Maria Grazia, van der Sluis, Inge, van Litsenburg, Raphaële, Vrooman, Lynda, Weinreb, Sigal, Wiener, Andreas, Winick, Naomi, Yano, Michihiro, Yeh, Ting-Chi, Zapotocka, Ester, Andrés-Jensen, Liv, Hagleitner, Melanie M, van Litsenburg, Raphaele R L, Hudson, Melissa M, Kremer, Leontien, Grazia Valsecchi, Maria, and Vrooman, Lynda M

Published
2021
Full Text
View/download PDF

11. Pharmacogenomic studies of fertility outcomes in pediatric cancer survivors – A systematic review.

Author

Stenta, Tayla, Assis, Michael, Ayers, Katie, Tucker, Elena J., Halman, Andreas, Gook, Debra, Sinclair, Andrew H., Elliott, David A., Jayasinghe, Yasmin, and Conyers, Rachel

Subjects
CANCER survivors, CHILDHOOD cancer, FERTILITY, CANCER prognosis, PREMATURE menopause, PREGNANCY
Abstract

For the same age, sex, and dosage, there can be significant variation in fertility outcomes in childhood cancer survivors. Genetics may explain this variation. This study aims to: (i) review the genetic contributions to infertility, (ii) search for pharmacogenomic studies looking at interactions of cancer treatment, genetic predisposition and fertility‐related outcomes. Systematic searches in MEDLINE Ovid, Embase Classic+Embase, and PubMed were conducted using the following selection criteria: (i) pediatric, adolescent, and young adult cancer survivors, below 25 years old at the time of diagnosis, (ii) fertility outcome measures after cancer therapy, (iii) genetic considerations. Studies were excluded if they were (i) conducted in animal models, (ii) were not published in English, (iii) editorial letters, (iv) theses. Articles were screened in Covidence by at least two independent reviewers, followed by data extraction and a risk of bias assessment using the Quality in Prognostic Studies tool. Eight articles were reviewed with a total of 29 genes. Outcome measures included sperm concentration, azoospermia, AMH levels, assessment of premature menopause, ever being pregnant or siring a pregnancy. Three studies included replication cohorts, which attempted replication of SNP findings for NPY2R, BRSK1, FANCI, CYP2C19, CYP3A4, and CYP2B6. Six studies were rated with a high risk of bias. Differing methods may explain a lack of replication, and small cohorts may have contributed to few significant findings. Larger, prospective longitudinal studies with an unbiased genome‐wide focus will be important to replicate significant results, which can be applied clinically. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Lessons Learnt in the First Year of an Australian Pediatric Cardio Oncology Clinic

Author

Toro, Claudia, primary, Felmingham, Ben, additional, Jhadav, Mangesh, additional, Celermajer, David S., additional, Gerche, Andre La, additional, O’Sullivan, John, additional, Kumar, Sanjeev, additional, Mateos, Marion K., additional, Fulbright, Joy, additional, Govender, Dinisha, additional, Collier, Lane, additional, Cheung, Michael, additional, Eisenstat, David, additional, Lange, Peter W., additional, Ayer, Julian, additional, Elliott, David A., additional, and Conyers, Rachel, additional

Published
2023
Full Text
View/download PDF

16. Integrating Cardio-Oncology Across the Research Pipeline, Policy, and Practice in Australia—An Australian Cardiovascular Alliance Perspective

Author

Kavurma, Mary, Pinto, Alex, Drummond, Grant, Ritchie, Rebecca, Barlis, Peter, Meikle, Peter, Jenkins, Alicia, Reid, Chris, Thijs, Vincent, Nedkoff, Lee, Cadilhac, Dominique, Jennings AO, Garry, Redfern, Julie, Singleton, Anna C., Diaz, Abbey, Koczwara, Bogda, Nicholls, Stephen J., Negishi, Kazuaki, La Gerche, Andre, Playford, David, Conyers, Rachel, Cehic, Daniel A., Garvey, Gail, Williams, Trent D., Hunt, Lee, Doyle, Kerry, Figtree, Gemma A., Ngo, Doan T.M., and Sverdlov, Aaron L.

Published
2024
Full Text
View/download PDF

17. Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome

Author

Gayden, Tenzin, Sepulveda, Fernando E., Khuong-Quang, Dong-Anh, Pratt, Jonathan, Valera, Elvis T., Garrigue, Alexandrine, Kelso, Susan, Sicheri, Frank, Mikael, Leonie G., Hamel, Nancy, Bajic, Andrea, Dali, Rola, Deshmukh, Shriya, Dervovic, Dzana, Schramek, Daniel, Guerin, Frédéric, Taipale, Mikko, Nikbakht, Hamid, Majewski, Jacek, Moshous, Despina, Charlebois, Janie, Abish, Sharon, Bole-Feysot, Christine, Nitschke, Patrick, Bader-Meunier, Brigitte, Mitchell, David, Thieblemont, Catherine, Battistella, Maxime, Gravel, Simon, Nguyen, Van-Hung, Conyers, Rachel, Diana, Jean-Sebastien, McCormack, Chris, Prince, H. Miles, Besnard, Marianne, Blanche, Stephane, Ekert, Paul G., Fraitag, Sylvie, Foulkes, William D., Fischer, Alain, Neven, Bénédicte, Michonneau, David, de Saint Basile, Geneviève, and Jabado, Nada

Published
2018
Full Text
View/download PDF

18. Physician-defined severe toxicities occurring during and after cancer treatment: Modified consensus definitions and clinical applicability in the evaluation of cancer treatment

Author

Nielsen, Camilla Grud, primary, Thomsen, Birthe Lykke, additional, Als-Nielsen, Bodil, additional, Conyers, Rachel, additional, Jeha, Sima, additional, Mateos, Marion K., additional, Mlynarski, Wojciech, additional, Pieters, Rob, additional, Rathe, Mathias, additional, Schmiegelow, Kjeld, additional, and Andrés-Jensen, Liv, additional

Published
2023
Full Text
View/download PDF

19. Physician-defined severe toxicities occurring during and after cancer treatment:Modified consensus definitions and clinical applicability in the evaluation of cancer treatment

Author

Nielsen, Camilla Grud, Thomsen, Birthe Lykke, Als-Nielsen, Bodil, Conyers, Rachel, Jeha, Sima, Mateos, Marion K., Mlynarski, Wojciech, Pieters, Rob, Rathe, Mathias, Schmiegelow, Kjeld, Andres-Jensen, Liv, Nielsen, Camilla Grud, Thomsen, Birthe Lykke, Als-Nielsen, Bodil, Conyers, Rachel, Jeha, Sima, Mateos, Marion K., Mlynarski, Wojciech, Pieters, Rob, Rathe, Mathias, Schmiegelow, Kjeld, and Andres-Jensen, Liv

Abstract

Overall survival after cancer is increasing for the majority of cancer types, but survivors can be burdened lifelong by treatment-related severe toxicities. Integration of long-term toxicities in treatment evaluation is not least important for children and young adults with cancers with high survival probability. We present modified consensus definitions of 21 previously published physician-defined Severe Toxicities (STs), each reflecting the most serious long-term treatment-related toxicities and representing an unacceptable price for cure. Applying the Severe Toxicity (ST) concept to real-world data required careful adjustments of the original consensus definitions, translating them into standardized endpoints for evaluating treatment-related outcomes to ensure that (1) the STs can be classified uniformly and prospectively across different cohorts, and (2) the ST definitions allow for valid statistical analyses. The current paper presents the resulting modified consensus definitions of the 21 STs proposed to be included in outcome reporting of cancer treatment., Overall survival after cancer is increasing for the majority of cancer types, but survivors can be burdened lifelong by treatment-related severe toxicities. Integration of long-term toxicities in treatment evaluation is not least important for children and young adults with cancers with high survival probability. We present modified consensus definitions of 21 previously published physician-defined Severe Toxicities (STs), each reflecting the most serious long-term treatment-related toxicities and representing an unacceptable price for cure. Applying the Severe Toxicity (ST) concept to real-world data required careful adjustments of the original consensus definitions, translating them into standardized endpoints for evaluating treatment-related outcomes to ensure that (1) the STs can be classified uniformly and prospectively across different cohorts, and (2) the ST definitions allow for valid statistical analyses. The current paper presents the resulting modified consensus definitions of the 21 STs proposed to be included in outcome reporting of cancer treatment.

Published
2023

22. Infections in children following chimeric antigen receptor T‐cell therapy for B‐cell acute lymphoblastic leukemia.

Author

Diamond, Yonatan, Gilsenan, Maddie, Wang, Stacie Shiqi, Hanna, Diane, Conyers, Rachel, Cole, Theresa, Hughes, David, Fleming, Jacqueline, Meyran, Deborah, Toro, Claudia, Malalasekera, Vajiranee, Khaw, Seong Lin, and Haeusler, Gabrielle M.

Subjects
CHIMERIC antigen receptors, LYMPHOBLASTIC leukemia, ACUTE leukemia, T cells, PULMONARY aspergillosis
Abstract

Background: CD19‐directed chimeric antigen receptor T‐cell (CAR‐T) therapy is transforming care for pediatric patients with relapsed or refractory B‐cell acute lymphoblastic leukemia (B‐ALL). There are limited pediatric‐specific data concerning the infection risks associated with CD19 CAR‐T therapy and the adequacy of current antimicrobial prophylaxis guidelines for these patients. Methods: We describe the antimicrobial prophylaxis used and the types of infectious occurring in the first 100 days following CAR‐T therapy for relapsed or refractory B‐cell ALL in children and adolescents (≤18 years) at our centre. Results: Twenty‐seven patients received their first CAR‐T infusion (CTI) during the study period. Almost all patients (96%) had a comprehensive Infectious Diseases review prior to CTI, which informed a personalised prophylaxis or fever/sepsis plan in six (22%). Overall, six (22%) patients had one or more infections during the study period including five (19%, 0.9 per 100 days‐at‐risk) from days 0–30 and three (n = 20, 15%, 0.6 per 100 days‐at‐risk) from days 31–100. Bacterial blood stream infections were the most common type of infection encountered during both time periods, and one patient had probable pulmonary aspergillosis. There were no infection‐related deaths. Conclusion: Our study contributes important information on the spectrum of infections encountered in pediatric patients with B‐ALL post CAR‐T therapy. Overall, the burden of infectious complications post CAR‐T therapy in our cohort is lower than previously reported in the literature. Results suggest that our prophylaxis recommendations are effective in this population. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

23. Density of antibiotic use and infectious complications in pediatric allogeneic hematopoietic cell transplantation

Author

Andrew, Eden C., primary, Khaw, Seong Lin, additional, Hanna, Diane, additional, Conyers, Rachel, additional, Fleming, Jacqueline, additional, Hughes, David, additional, Toro, Claudia, additional, Wang, Stacie Shiqi, additional, Weerdenburg, Heather, additional, Anderson, Sally, additional, Cole, Theresa, additional, and Haeusler, Gabrielle M, additional

Published
2023
Full Text
View/download PDF

26. Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID‐19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell

Author

Perram, Jacinta, primary, Purtill, Duncan, additional, Bajel, Ashish, additional, Butler, Jason, additional, O'Brien, Tracey, additional, Teh, Benjamin, additional, Gilroy, Nicole, additional, Ho, Phoebe J., additional, Doocey, Richard, additional, Hills, Thomas, additional, Perera, Travis, additional, Douglas, Genevieve, additional, Ramachandran, Shanti, additional, Chee, Lynette, additional, Trotman, Judith, additional, Weinkove, Robert, additional, Keogh, Steven, additional, Fraser, Chris, additional, Cochrane, Tara, additional, Watson, Anne‐Marie, additional, Diamond, Peter, additional, Latimer, Maya, additional, Irving, Ian, additional, Blyth, Emily, additional, Cheah, Chan, additional, Cole, Theresa, additional, Milliken, Sam, additional, Yang, Hung, additional, Greenwood, Matthew, additional, Bardy, Peter, additional, Kennedy, Glen, additional, Larsen, Stephen, additional, Conyers, Rachel, additional, and Hamad, Nada, additional

Published
2023
Full Text
View/download PDF

32. Additional file 1 of Prospective longitudinal evaluation of treatment-related toxicity and health-related quality of life during the first year of treatment for pediatric acute lymphoblastic leukemia

Author

Schilstra, Clarissa E., McCleary, Karen, Fardell, Joanna E., Donoghoe, Mark W., McCormack, Emma, Kotecha, Rishi S., Lourenco, Richard De Abreu, Ramachandran, Shanti, Cockcroft, Ruelleyn, Conyers, Rachel, Cross, Siobhan, Dalla-Pozza, Luciano, Downie, Peter, Revesz, Tamas, Osborn, Michael, Alvaro, Frank, Wakefield, Claire E., Marshall, Glenn M., Mateos, Marion K., and Trahair, Toby N.

Abstract

Additional file 1: Supplementary Table 1. ASSET Health-Related Quality of Life Outcomes (PedsQL Cancer Module and HUI3). Supplementary Table 2. Parents’ emotional well-being (ET). Supplementary Table 3. COG vs. iBFM Protocol Group Health-Related Quality of Life Comparisons (HUI3, PedsQL & PedsQL Nausea, Pain & Procedural Anxiety subscales). Supplementary Table 4. COG vs. iBFM Protocol Group Health Related Quality of Life Comparisons (PedsQL Anxiety, Worry, Cognitive Functioning, Physical appearance & Communication subscales). Supplementary Table 5. COG vs. iBFM Protocol group parental emotional well-being comparisons (ET).

Published
2022
Full Text
View/download PDF

33. Additional file 2 of Prospective longitudinal evaluation of treatment-related toxicity and health-related quality of life during the first year of treatment for pediatric acute lymphoblastic leukemia

Author

Schilstra, Clarissa E., McCleary, Karen, Fardell, Joanna E., Donoghoe, Mark W., McCormack, Emma, Kotecha, Rishi S., Lourenco, Richard De Abreu, Ramachandran, Shanti, Cockcroft, Ruelleyn, Conyers, Rachel, Cross, Siobhan, Dalla-Pozza, Luciano, Downie, Peter, Revesz, Tamas, Osborn, Michael, Alvaro, Frank, Wakefield, Claire E., Marshall, Glenn M., Mateos, Marion K., and Trahair, Toby N.

Abstract

Additional file 2: Data Table 1. HUI3 Data. Data Table 2. PedsQL Cancer Data. Data Table 3. Emotion Thermometer Data.

Published
2022
Full Text
View/download PDF

34. Author Correction: Germline HAVCR2 mutations altering TIM-3 characterize subcutaneous panniculitis-like T cell lymphomas with hemophagocytic lymphohistiocytic syndrome

Author

Gayden, Tenzin, Sepulveda, Fernando E., Khuong-Quang, Dong-Anh, Pratt, Jonathan, Valera, Elvis T., Garrigue, Alexandrine, Kelso, Susan, Sicheri, Frank, Mikael, Leonie G., Hamel, Nancy, Bajic, Andrea, Dali, Rola, Deshmukh, Shriya, Dervovic, Dzana, Schramek, Daniel, Guerin, Frédéric, Taipale, Mikko, Nikbakht, Hamid, Majewski, Jacek, Moshous, Despina, Charlebois, Janie, Abish, Sharon, Bole-Feysot, Christine, Nitschke, Patrick, Bader-Meunier, Brigitte, Mitchell, David, Thieblemont, Catherine, Battistella, Maxime, Gravel, Simon, Nguyen, Van-Hung, Conyers, Rachel, Diana, Jean-Sebastien, McCormack, Chris, Prince, H. Miles, Besnard, Marianne, Blanche, Stephane, Ekert, Paul G., Fraitag, Sylvie, Foulkes, William D., Fischer, Alain, Neven, Bénédicte, Michonneau, David, de Saint Basile, Geneviève, and Jabado, Nada

Published
2019
Full Text
View/download PDF

35. COVID‐19 vaccination in children and adolescents aged 5 years and older undergoing treatment for cancer and non‐malignant haematological conditions: Australian and New Zealand Children’s Haematology/Oncology Group consensus statement

Author

Furlong, Eliska, primary, Kotecha, Rishi S, additional, Conyers, Rachel, additional, O'Brien, Tracey A, additional, Hansford, Jordan R, additional, Super, Leanne, additional, Downie, Peter, additional, Eisenstat, David D, additional, Haeusler, Gabrielle, additional, McMullan, Brendan, additional, Phillips, Marianne B, additional, Padhye, Bhavna, additional, Dalla‐Pozza, Luciano, additional, Alvaro, Frank, additional, Fraser, Christopher J, additional, Nicholls, Wayne, additional, Clark, Julia E, additional, O'Connor, Matthew, additional, Saxon, Benjamin R, additional, Tapp, Heather, additional, Heath, John, additional, Hunter, Sarah E, additional, Tsui, Karen, additional, Winstanley, Mark, additional, Lyver, Amanda, additional, Best, Emma J, additional, Wadia, Ushma, additional, Yeoh, Daniel, additional, Blyth, Christopher C, additional, and Gottardo, Nicholas G, additional

Published
2022
Full Text
View/download PDF

38. Australia and New Zealand Transplant and Cellular Therapies COVID‐19 vaccination consensus position statement

Author

Hamad, Nada, primary, Ananda‐Rajah, Michelle, additional, Gilroy, Nicole, additional, MacIntyre, Raina, additional, Gottlieb, David, additional, Ritchie, David, additional, Harrison, Simon, additional, Kennedy, Glen, additional, Watson, Anne M., additional, Greenwood, Matthew, additional, Doocey, Richard, additional, Perera, Travis, additional, Spencer, Andrew, additional, Wong, Eric, additional, O'Brien, Tracey, additional, Shaw, Peter, additional, Conyers, Rachel, additional, Milliken, Samuel, additional, Bardy, Peter, additional, Larsen, Stephen, additional, Ho, Phoebe J., additional, Lai, Hock, additional, Bajel, Ashish, additional, Butler, Jason, additional, Tiley, Campbell, additional, D'Rozario, James, additional, Johnston, Anna, additional, Cochrane, Tara, additional, Mills, Tony, additional, Irving, Ian, additional, Pullon, Humprey, additional, and Purtill, Duncan, additional

Published
2021
Full Text
View/download PDF

39. Severe toxicity free survival: physician-derived definitions of unacceptable long-term toxicities following acute lymphocytic leukaemia

Author

Andrés-Jensen, Liv, primary, Attarbaschi, Andishe, additional, Bardi, Edit, additional, Barzilai-Birenboim, Shlomit, additional, Bhojwani, Deepa, additional, Hagleitner, Melanie M, additional, Halsey, Christina, additional, Harila-Saari, Arja, additional, van Litsenburg, Raphaele R L, additional, Hudson, Melissa M, additional, Jeha, Sima, additional, Kato, Motohiro, additional, Kremer, Leontien, additional, Mlynarski, Wojciech, additional, Möricke, Anja, additional, Pieters, Rob, additional, Piette, Caroline, additional, Raetz, Elizabeth, additional, Ronceray, Leila, additional, Toro, Claudia, additional, Grazia Valsecchi, Maria, additional, Vrooman, Lynda M, additional, Weinreb, Sigal, additional, Winick, Naomi, additional, Schmiegelow, Kjeld, additional, Adams, Madeline R, additional, Andres-Jensen, Liv, additional, Baust, Katja, additional, Boesten, Tineke, additional, Calaminus, Gabriele, additional, Conyers, Rachel, additional, Darlington, Anne-Sophie, additional, de Ville, Maëlle, additional, Escherich, Gabriele, additional, Hagleitner, Melanie, additional, Hou, Jen-Yin, additional, Huang, Ting-Huan, additional, Hudson, Melissa, additional, Jenney, Meriel, additional, Krawczuk-Rybak, Maryna, additional, Kremer, Leontine, additional, Lautem, Melchior, additional, Liu, Hse-Che, additional, Lopez Lopez, Elixabet, additional, Mateos, Marion, additional, Muszynska-Roslan, Katarzyna, additional, Niinimaki, Riitta, additional, Trahair, Toby, additional, Valsecchi, Maria Grazia, additional, van der Sluis, Inge, additional, van Litsenburg, Raphaële, additional, Vrooman, Lynda, additional, Wiener, Andreas, additional, Yano, Michihiro, additional, Yeh, Ting-Chi, additional, and Zapotocka, Ester, additional

Published
2021
Full Text
View/download PDF

41. The Australia and New Zealand Cardio-Oncology Registry: Evaluation of chemotherapy‐related cardiotoxicity in a national cohort of paediatric cancer patients

Author

Lapirow, Daniel, La Gerche, Andre, Toro, Claudia, Masango, Emma, Costello, Ben, Porello, Enzo, Ludlow, Louise, Marshall, Glenn, Trahair, Toby, Mateos, Marion, Lewin, Jeremy, Byrne, Jennifer, Boutros, Rose, Manudhane, Rebecca, Heath, John, Ayer, Julian, Gabriel, Melissa, Walwyn, Thomas, Saundankar, Jelena, Forsey, Jonathon, Le, Ha, Mason, Kylie, Celermajer, David, Downie, Peter, Walker, Roderick, Holland, Lucy, Martin, Michelle, Mcleman, Lorna, Diamond, Yonatan, Marcocci, Maurizio, Donath, Susan, Cheung, Michael, Elliott, David A., Conyers, Rachel, Lapirow, Daniel, La Gerche, Andre, Toro, Claudia, Masango, Emma, Costello, Ben, Porello, Enzo, Ludlow, Louise, Marshall, Glenn, Trahair, Toby, Mateos, Marion, Lewin, Jeremy, Byrne, Jennifer, Boutros, Rose, Manudhane, Rebecca, Heath, John, Ayer, Julian, Gabriel, Melissa, Walwyn, Thomas, Saundankar, Jelena, Forsey, Jonathon, Le, Ha, Mason, Kylie, Celermajer, David, Downie, Peter, Walker, Roderick, Holland, Lucy, Martin, Michelle, Mcleman, Lorna, Diamond, Yonatan, Marcocci, Maurizio, Donath, Susan, Cheung, Michael, Elliott, David A., and Conyers, Rachel

Abstract

Cancer therapy related cardiac dysfunction (CTRCD) is an area of increasing focus, particularly during the survivorship period, for paediatric, adolescent and adult cancer survivors. With the advent of immunotherapy and targeted therapy, there is a new set of mechanisms from which paediatric and young adult patients with cancer may suffer cardiovascular injury. Furthermore, cardiovascular disease is the leading cause of morbidity and mortality in the survivorship period. The recently established Australian Cardio-Oncology Registry is the largest and only population-based cardiotoxicity database of paediatric and adolescent and young adult oncology patients in the world, and the first paediatric registry that will document cardiotoxicity caused by chemotherapy and novel targeted therapies using a prospective approach. The database is designed for comprehensive data collection and evaluation of the Australian practice in terms of diagnosis and management of CTRCD. Using the Australian Cardio-Oncology Registry critical clinical information will be collected regarding predisposing factors for the development of CTRCD, the rate of subclinical left ventricular dysfunction and transition to overt heart failure, further research into protectant molecules against cardiac dysfunction and aid in the discovery of which genetic variants predispose to CTRCD. A health economic arm of the study will assess the cost/benefit of both the registry and cardio-oncology clinical implementation. Finally, an imaging arm will establish if exercise cardiac magnetic resonance imaging and VO2 max testing is a more sensitive predictor of cardiac reserve in paediatric and adolescent and young adult oncology patients exposed to cardiac toxic therapies.

Published
2021

42. Optimal Detection of Cardiac Sequelae The Need for Rigorous, Harmonized Magnetic Resonance Studies in Pediatric Survivors

Author

Toro, Claudia, Elliott, David A, La Gerche, Andre, Lange, Peter W, Bolk, Francesca, O'Sullivan, Michael, Bhatia, Kanika, and Conyers, Rachel

Subjects
cancer survivorship, Science & Technology, Cardiac & Cardiovascular Systems, Oncology, CHILDHOOD-CANCER, screening, Cardiovascular System & Cardiology, comparative effectiveness, ECHOCARDIOGRAPHY, Life Sciences & Biomedicine, cardiomyopathy, cardiac magnetic resonance
Abstract

ispartof: JACC: CARDIOONCOLOGY vol:3 issue:1 pages:154-156 ispartof: location:United States status: published

Published
2021

43. Treatment and Outcomes for Central Nervous System Tumors in Australian Adolescents and Young Adults: A Population-Based National Study

Author

Harrup, Rosemary, primary, White, Victoria M., additional, Coory, Michael, additional, Walker, Rick, additional, Anazodo, Antoinette, additional, Skaczkowski, Gemma, additional, Bibby, Helen, additional, Osborn, Michael, additional, Phillips, Marianne B., additional, Conyers, Rachel, additional, Thompson, Kate, additional, Orme, Lisa M., additional, Pinkerton, Ross, additional, and Nicholls, Wayne, additional

Published
2021
Full Text
View/download PDF

44. Optimal Detection of Cardiac Sequelae

Author

Toro, Claudia, primary, Elliott, David A., additional, La Gerche, Andre, additional, Lange, Peter W., additional, Bsc, Francesca Bolk, additional, O’Sullivan, Michael, additional, Bhatia, Kanika, additional, and Conyers, Rachel, additional

Published
2021
Full Text
View/download PDF

45. The Australia and New Zealand Cardio‐Oncology Registry: evaluation of chemotherapy‐related cardiotoxicity in a national cohort of paediatric cancer patients

Author

Lapirow, Daniel, primary, La Gerche, Andre, additional, Toro, Claudia, additional, Masango, Emma, additional, Costello, Ben, additional, Porello, Enzo, additional, Ludlow, Louise, additional, Marshall, Glenn, additional, Trahair, Toby, additional, Mateos, Marion, additional, Lewin, Jeremy, additional, Byrne, Jennifer, additional, Boutros, Rose, additional, Manudhane, Rebecca, additional, Heath, John, additional, Ayer, Julian, additional, Gabriel, Melissa, additional, Walwyn, Thomas, additional, Saundankar, Jelena, additional, Forsey, Jonathon, additional, Le, Ha, additional, Mason, Kylie, additional, Celermajer, David, additional, Downie, Peter, additional, Walker, Roderick, additional, Holland, Lucy, additional, Martin, Michelle, additional, McLeman, Lorna, additional, Diamond, Yonatan, additional, Marcocci, Maurizio, additional, Donath, Susan, additional, Cheung, Michael, additional, Elliott, David A., additional, and Conyers, Rachel, additional

Published
2021
Full Text
View/download PDF

46. Additional file 1 of Evaluating anthracycline cardiotoxicity associated single nucleotide polymorphisms in a paediatric cohort with early onset cardiomyopathy

Author

McOwan, Timothy N., Craig, Lauren A., Tripdayonis, Anne, Karavendzas, Kathy, Cheung, Michael M., Porrello, Enzo R., Conyers, Rachel, and Elliott, David A.

Abstract

Additional file 1: Table S1. Primers amplifying DNA including the identified SNP for identification of previously identified missense variants associated with anthracycline cardiotoxicity. Table S2. Sex, age at diagnosis and tumour type of study cohort*. Table S3. Published single nucleotide polymorphisms (SNPs) associated with anthracycline-induced cardiotoxicity

Published
2020
Full Text
View/download PDF

49. Bone Marrow Transplant Society of Australia and New Zealand COVID‐19 consensus position statement

Author

Hamad, Nada, primary, Gottlieb, David, additional, Ritchie, David, additional, Kennedy, Glen, additional, Watson, Anne M., additional, Greenwood, Matthew, additional, Doocey, Richard, additional, Perera, Travis, additional, Spencer, Andrew, additional, Wong, Eric, additional, O'Brien, Tracey, additional, Shaw, Peter, additional, Conyers, Rachel, additional, Cole, Theresa, additional, Milliken, Sam, additional, Bardy, Peter, additional, Larsen, Stephen, additional, Lai, Hock, additional, Butler, Andrew, additional, Fraser, Chris, additional, Bajel, Ashish, additional, Butler, Jason, additional, Kerridge, Ian, additional, and Purtill, Duncan, additional

Published
2020
Full Text
View/download PDF

50. Managing haematology and oncology patients during the COVID ‐19 pandemic: interim consensus guidance

Author

Weinkove, Robert, primary, McQuilten, Zoe K, additional, Adler, Jonathan, additional, Agar, Meera R, additional, Blyth, Emily, additional, Cheng, Allen C, additional, Conyers, Rachel, additional, Haeusler, Gabrielle M, additional, Hardie, Claire, additional, Jackson, Christopher, additional, Lane, Steven W, additional, Middlemiss, Tom, additional, Mollee, Peter, additional, Mulligan, Stephen P, additional, Ritchie, David, additional, Ruka, Myra, additional, Solomon, Benjamin, additional, Szer, Jeffrey, additional, Thursky, Karin A, additional, Wood, Erica M, additional, Worth, Leon J, additional, Yong, Michelle K, additional, Slavin, Monica A, additional, and Teh, Benjamin W, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results